Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease

NCT02505568 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.

NCT NCT02505568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02505568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Lead sponsor
Janssen Korea, Ltd., Korea
Phase
Phase 3
Overall status
Completed
Start date
July 22, 2015
Completion date
July 13, 2018
Enrollment
33 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

behcet disease